Preventive effect of α-lipoic acid on prepulse inhibition deficits in a juvenile two-hit model of schizophrenia

Neuroscience

Volumn 272, Issue , 2014, Pages 261-270

  Deslauriers, J ^a   Racine, W ^a,b   Sarret, P ^a   Grignon, S ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Dopamine D2 receptor; GAD67; Lipoic acid; Prepulse inhibition; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; GLUTAMATE DECARBOXYLASE 67; THIOCTIC ACID; DOPAMINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; IMMOBILIZATION STRESS; IN VIVO STUDY; JUVENILE ANIMAL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRENATAL EXPOSURE; PREPULSE INHIBITION; PREPULSE INHIBITION DEFICIT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; REGULATORY MECHANISM; SCHIZOPHRENIA; AGING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; PATHOPHYSIOLOGY; PREGNANCY; STARTLE REFLEX;

AGING; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE, INBRED C57BL; PREFRONTAL CORTEX; PREGNANCY; RECEPTORS, DOPAMINE; REFLEX, STARTLE; SCHIZOPHRENIA; THIOCTIC ACID;

EID: 84901363276     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.04.061     Document Type: Article

References (65)

1. Akpinar D., Yargicoglu P., Derin N., Aliciguzel Y., Sahin M., Agar A. The effect of lipoic acid on lipid peroxidation and visual evoked potentials (VEPs) in rats exposed to chronic restraint stress. Int J Neurosci 2007, 117(12):1691-1706.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67(2):146-154.
3. Bayer S.A., Wills K.V., Triarhou L.C., Ghetti B. Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res 1995, 105(2):191-199.
4. Bayer T.A., Falkai P., Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 1999, 33(6):543-548.
5. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., Dugan L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318(5856):1645-1647.
6. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13(1):76-83.
7. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A 2007, 104(24):10164-10169.
8. Boksa P. Maternal infection during pregnancy and schizophrenia. J Psychiatry Neurosci 2008, 33(3):183-185.
9. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., Babulas V.P., Susser E.S. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004, 61(8):774-780.
10. Brown A.S., Schaefer C.A., Wyatt R.J., Goetz R., Begg M.D., Gorman J.M., Susser E.S. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 2000, 26(2):287-295.
11. Cadenhead K.S. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res 2011, 188(2):208-216.
12. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001, 41:237-260.
13. Deslauriers J., Desmarais C., Sarret P., Grignon S. Alpha-lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3beta signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia. J Mol Neurosci 2012.
14. Deslauriers J., Larouche A., Sarret P., Grignon S. Combination of prenatal immune challenge and restraint stress affects prepulse inhibition and dopaminergic/GABAergic markers. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45C:156-164.
15. Deslauriers J., Lefrancois M., Larouche A., Sarret P., Grignon S. Antipsychotic-induced DRD2 upregulation and its prevention by alpha-lipoic acid in SH-SY5Y neuroblastoma cells. Synapse 2011, 65(4):321-331.
16. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12(10):3721-3728.
17. Eranti S.V., Maccabe J.H., Bundy H., Murray R.M. Gender difference in age at onset of schizophrenia: a meta-analysis. Psychol Med 2013, 43(1):155-167.
18. Flaum M., Andreasen N.C. Diagnostic criteria for schizophrenia and related disorders: options for DSM-IV. Schizophr Bull 1991, 17(1):133-156.
19. Geyer M.A. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps. Neurotox Res 2006, 10(3-4):211-220.
20. Gogtay N., Vyas N.S., Testa R., Wood S.J., Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull 2011, 37(3):504-513.
21. Goldsmith S.K., Shapiro R.M., Joyce J.N. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch Gen Psychiatry 1997, 54(7):649-658.
22. Grima G., Benz B., Parpura V., Cuenod M., Do K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 2003, 62(3):213-224.
23. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003, 23(15):6315-6326.
24. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012, 69(8):776-786.
25. Kim E., Park D.W., Choi S.H., Kim J.J., Cho H.S. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. J Clin Psychopharmacol 2008, 28(2):138-146.
26. Kim S.T., Choi J.H., Chang J.W., Kim S.W., Hwang O. Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system. J Neurochem 2005, 95(1):89-98.
27. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 2006, 26(5):1604-1615.
28. Klosterkotter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001, 58(2):158-164.
29. Knable M.B., Barci B.M., Bartko J.J., Webster M.J., Torrey E.F. Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers. Mol Psychiatry 2002, 7(4):392-404.
30. Larouche A., Berube P., Sarret P., Grignon S. Subacute H2O2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse 2008, 62(1):70-73.
31. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998, 42(3):211-221.
32. Li Q., Guo M., Xu X., Xiao X., Xu W., Sun X., Tao H., Li R. Rapid decrease of GAD 67 content before the convulsion induced by hyperbaric oxygen exposure. Neurochem Res 2008, 33(1):185-193.
33. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43(9):674-679.
34. Marti J., Wills K.V., Ghetti B., Bayer S.A. A combined immunohistochemical and autoradiographic method to detect midbrain dopaminergic neurons and determine their time of origin. Brain Res Brain Res Protoc 2002, 9(3):197-205.
35. Maynard T.M., Sikich L., Lieberman J.A., LaMantia A.S. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull 2001, 27(3):457-476.
36. McDonald C., Murray R.M. Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev 2000, 31(2-3):130-137.
37. Meyer U., Feldon J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 2012, 62(3):1308-1321.
38. Meyer U., Nyffeler M., Yee B.K., Knuesel I., Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008, 22(4):469-486.
39. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28(1):53-67.
40. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. Br Med J (Clin Res Ed) 1987, 295(6600):681-682.
41. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11(6):851-876.
42. O'Callaghan E., Sham P.C., Takei N., Murray G., Glover G., Hare E.H., Murray R.M. The relationship of schizophrenic births to 16 infectious diseases. Br J Psychiatry 1994, 165(3):353-356.
43. Opler M.G., Susser E.S. Fetal environment and schizophrenia. Environ Health Perspect 2005, 113(9):1239-1242.
44. Packer L., Tritschler H.J. Alpha-lipoic acid: the metabolic antioxidant. Free Radic Biol Med 1996, 20(4):625-626.
45. Packer L., Witt E.H., Tritschler H.J. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995, 19(2):227-250.
46. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2008, Elsevier. third edition.
47. Petersen Shay K., Moreau R.F., Smith E.J., Hagen T.M. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 2008, 60(6):362-367.
48. Picchioni M.M., Murray R.M. Schizophrenia. BMJ 2007, 335(7610):91-95.
49. Quednow B.B., Frommann I., Berning J., Kühn K.U., Maier W., Wagner M. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biol Psychiatry 2008, 64(9):766-773.
50. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 2012, 17(12):1228-1238.
51. Ratliff J.C., Palmese L.B., Reutenauer E.L., Tek C. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses 2013, 1-13.
52. Reynolds G.P., Beasley C.L. GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J Chem Neuroanat 2001, 22(1-2):95-100.
53. Sedlak T.W., Saleh M., Higginson D.S., Paul B.D., Juluri K.R., Snyder S.H. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci U S A 2009, 106(13):5171-5176.
54. Shi L., Fatemi S.H., Sidwell R.W., Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003, 23(1):297-302.
55. Srihari V.H., Shah J., Keshavan M.S. Is early intervention for psychosis feasible and effective?. Psychiatr Clin North Am 2012, 35(3):613-631.
56. Suvisaari J., Haukka J., Tanskanen A., Hovi T., Lonnqvist J. Association between prenatal exposure to poliovirus infection and adult schizophrenia. Am J Psychiatry 1999, 156(7):1100-1102.
57. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 1998, 24(2):285-301.
58. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 2008, 199(3):331-388.
59. Tallerico T., Novak G., Liu I.S., Ulpian C., Seeman P. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res 2001, 87(2):160-165.
60. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005, 57(3):252-260.
61. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44(7):660-669.
62. Weinberger D.R. From neuropathology to neurodevelopment. Lancet 1995, 346(8974):552-557.
63. Wolf R., Matzke K., Paelchen K., Dobrowolny H., Bogerts B., Schwegler H. Reduction of prepulse inhibition (PPI) after neonatal excitotoxic lesion of the ventral thalamus in pubertal and adult rats. Pharmacopsychiatry 2010, 43(3):99-109.
64. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32(1):1-8.
65. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15(4):287-310.